View Financial HealthDx & Vx 배당 및 자사주 매입배당 기준 점검 0/6Dx & Vx 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-38.6%자사주 매입 수익률총 주주 수익률-38.6%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 17Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South KoreaNew Risk • Jan 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding).New Risk • Dec 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩25b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years.공시 • Dec 23Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering.Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 49,210,000 Transaction Features: Subsequent Direct ListingNew Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩111.5b market cap, or US$75.4m).분석 기사 • Dec 18The Market Doesn't Like What It Sees From Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues YetDx & Vx Co., Ltd.'s ( KOSDAQ:180400 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...New Risk • Nov 29New major risk - Negative shareholders equityThe company has negative equity. Total equity: -₩3.2b This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩88.4b market cap, or US$60.2m).분석 기사 • Aug 20There's No Escaping Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Muted Revenues Despite A 28% Share Price RiseKOSDAQ:A180400 1 Year Share Price vs Fair Value Explore Dx & Vx's Fair Values from the Community and select yours Dx...분석 기사 • Aug 18We Think Dx & Vx (KOSDAQ:180400) Has A Fair Chunk Of DebtKOSDAQ:A180400 1 Year Share Price vs Fair Value Explore Dx & Vx's Fair Values from the Community and select yours Some...New Risk • Jul 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Earnings have declined by 40% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩132.4b market cap, or US$95.9m).공시 • May 30Dx&Vx Accelerates Development of Universal COVID-19 VaccineDx&Vx (DXVX) has officially announced the acceleration of its development program for a universal COVID-19 vaccine, following the recent acquisition of related technology. Designed to provide immunity against both current and future variants of the coronavirus, this next-generation vaccine is drawing global attention amid a new wave of COVID-19 cases worldwide. Global health organizations, including the WHO, have raised concerns about rising COVID-19 cases in parts of Europe, Asia, and North America. These warnings have highlighted the urgent need for more robust and lasting immune solutions against evolving virus variants. Currently, DXVX is advancing through the regulatory procedures necessary to initiate Phase 2 clinical trials in South Korea, the U.S., and Southeast Asia. After successfully completing Phase 1 trials in the U.S. and South Africa, the company is preparing its Investigational New Drug (IND) applications for global Phase 2 studies.공시 • Mar 12Dx & Vx Co., Ltd., Annual General Meeting, Mar 28, 2025Dx & Vx Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea분석 기사 • Feb 14Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 32% LowerThe Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...New Risk • Feb 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩65.0b market cap, or US$45.1m).분석 기사 • Feb 12Is Dx & Vx (KOSDAQ:180400) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Dec 05Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 28%The Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...New Risk • Nov 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩93.1b market cap, or US$66.7m).분석 기사 • Oct 21Positive Sentiment Still Eludes Dx & Vx Co., Ltd. (KOSDAQ:180400) Following 27% Share Price SlumpDx & Vx Co., Ltd. ( KOSDAQ:180400 ) shareholders that were waiting for something to happen have been dealt a blow with...공시 • Oct 04Dx & Vx Co., Ltd. (KOSDAQ:A180400) agreed to acquire remaining 37% stake in Avixgen, Inc. for KRW 4.7 billion.Dx & Vx Co., Ltd. (KOSDAQ:A180400) agreed to acquire remaining 37% stake in Avixgen, Inc. for KRW 4.7 billion on October 2, 2024. The consideration consists of 1.7 million common equity of Dx & Vx Co., Ltd. at a ratio of 0.290319 per common equity of Avixgen, Inc. The merger agreement is expected to signed on October 4, 2024. The expected completion of the transaction is December 17, 2024.New Risk • Oct 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩131.4b market cap, or US$98.6m).공시 • Sep 13Dx & Vx Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 42.37 billion.Dx & Vx Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 42.37 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 18,385,983 Price\Range: KRW 2230 Discount Per Security: KRW 44.6 Security Name: Common Stock Security Type: Common Stock Securities Offered: 614,017 Price\Range: KRW 2230 Discount Per Security: KRW 44.6 Transaction Features: Rights OfferingNew Risk • Aug 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩111.4b market cap, or US$83.4m).공시 • Jul 19DX&VX Is on Track and Accelerating the Development of Oral Obesity TreatmentDX&VX, which is gaining attention for developing an oral GLP-1 obesity treatment. The company is accelerating the optimization of new drug candidates. GLP-1 (glucagon-like peptide-1), an oral obesity treatment drug being developed by DX&VX, is a hormone that induces weight loss by suppressing appetite and increasing satiety to treat obesity. DX&VX researchers have developed organic compounds that can be taken orally once a day instead of through injections. While obesity treatment drug developers are conducting clinical trials for new oral GLP-1 organic compound drugs, the importance of this field is expanding day by day. To date, DX&VX has secured excellent candidate substances based on its AI-based innovative new drug design technology, and plans to submit patents for at least two more substances within this year. This research outcome is receiving significant attention from the industry and many pharmaceutical companies, both domestically and internationally, with some companies exploring the possibility of cooperation with DX&VX. Based on these achievements, DX&VX is expected to further accelerate the development of oral GLP-1 obesity treatments by utilizing various options such as early licensing out, global joint clinical trials, and research funding investment. As additional research results and patent applications continue, the obesity treatment drug being developed byDX&VX is expected to have stronger market competitiveness in the future.분석 기사 • Jul 15Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 39% LowerUnfortunately for some shareholders, the Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has dived 39% in the last...분석 기사 • May 31Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 37%The Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...New Risk • May 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Market cap is less than US$100m (₩84.6b market cap, or US$61.5m).New Risk • May 29New major risk - Revenue and earnings growthEarnings have declined by 9.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Market cap is less than US$100m (₩123.9b market cap, or US$90.8m).Reported Earnings • Mar 23Full year 2023 earnings released: ₩929 loss per share (vs ₩47.45 loss in FY 2022)Full year 2023 results: ₩929 loss per share (further deteriorated from ₩47.45 loss in FY 2022). Revenue: ₩46.7b (up 45% from FY 2022). Net loss: ₩27.5b (loss widened ₩26.1b from FY 2022).분석 기사 • Mar 18Investors Give Dx & Vx Co., Ltd. (KOSDAQ:180400) Shares A 25% HidingTo the annoyance of some shareholders, Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) shares are down a considerable 25% in the...분석 기사 • Mar 08Dx & Vx (KOSDAQ:180400) Is Carrying A Fair Bit Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Oct 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).New Risk • Jun 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).공시 • Jun 15Dx & Vx Co., Ltd. announced that it has received KRW 9.223311402 billion in funding from Renaissance Asset Management and other investorsOn June 14, 2023, Dx & Vx Co., Ltd. closed the transaction.공시 • May 25Dx & Vx Co., Ltd. (KOSDAQ:A180400) acquired Avixgen, IncDx & Vx Co., Ltd. (KOSDAQ:A180400) acquired Avixgen, Inc. recently.공시 • May 17+ 1 more updateDxVx Appoints Kevin Kwon as New PresidentDxVx announced on May 16, 2023, the board of directors appointed Kevin Kwon, the former head of global business division at Hanmi Pharm.Co.,Ltd., as the new president. The new president, Kevin Kwon, holds a bachelor's and master's degree in applied bio-chemistry from Seoul National University, as well as a doctorate in management of technology from Korea University. He worked at the LG Chemical Biotech Research Institute and Regulatory Affairs (RA) Team in the LG Life Science. At Hanmi Pharm.Co.,Ltd, he served as the head of the global business division. He was a key person in global pharmaceutical business operations including global RA, overseas business development, overseas sales, clinical trials for new drug and licensing activities. In his career, he served as a joint professor at the Korea University Engineering Graduate School, an advisor for Korea Innovative Medicine Consortium (KimCo), an advisor for the formulation of bio similar regulations for the Ministry of Food and Drug Safety, a delegate for opening global markets at the Korea Health Industry Development Institute, and a professor for academic and business cooperation at Catholic University. Currently, he serves as a member of the special committee for global expansion at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. New president Kevin Kwon will be appointed as a board director from a shareholders' meeting. The former CEO, Sang Tae Park, has been nominated for the board director at Avixgen. In his new role, he intends to continue to make contributions to the company's growth by taking the lead in advancing the pipeline for new drugs and establishing a presence in the North American market.Board Change • Apr 04Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 A180400 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: A180400 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Dx & Vx 배당 수익률 vs 시장A180400의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (A180400)n/a시장 하위 25% (KR)1.1%시장 상위 25% (KR)4.0%업계 평균 (Biotechs)0.5%분석가 예측 (A180400) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 A180400 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 A180400 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 A180400 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: A180400 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YKR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/16 02:41종가2026/06/16 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Dx & Vx Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 17Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea
New Risk • Jan 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding).
New Risk • Dec 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩25b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years.
공시 • Dec 23Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering.Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 49,210,000 Transaction Features: Subsequent Direct Listing
New Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩111.5b market cap, or US$75.4m).
분석 기사 • Dec 18The Market Doesn't Like What It Sees From Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues YetDx & Vx Co., Ltd.'s ( KOSDAQ:180400 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...
New Risk • Nov 29New major risk - Negative shareholders equityThe company has negative equity. Total equity: -₩3.2b This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩88.4b market cap, or US$60.2m).
분석 기사 • Aug 20There's No Escaping Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Muted Revenues Despite A 28% Share Price RiseKOSDAQ:A180400 1 Year Share Price vs Fair Value Explore Dx & Vx's Fair Values from the Community and select yours Dx...
분석 기사 • Aug 18We Think Dx & Vx (KOSDAQ:180400) Has A Fair Chunk Of DebtKOSDAQ:A180400 1 Year Share Price vs Fair Value Explore Dx & Vx's Fair Values from the Community and select yours Some...
New Risk • Jul 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Earnings have declined by 40% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩132.4b market cap, or US$95.9m).
공시 • May 30Dx&Vx Accelerates Development of Universal COVID-19 VaccineDx&Vx (DXVX) has officially announced the acceleration of its development program for a universal COVID-19 vaccine, following the recent acquisition of related technology. Designed to provide immunity against both current and future variants of the coronavirus, this next-generation vaccine is drawing global attention amid a new wave of COVID-19 cases worldwide. Global health organizations, including the WHO, have raised concerns about rising COVID-19 cases in parts of Europe, Asia, and North America. These warnings have highlighted the urgent need for more robust and lasting immune solutions against evolving virus variants. Currently, DXVX is advancing through the regulatory procedures necessary to initiate Phase 2 clinical trials in South Korea, the U.S., and Southeast Asia. After successfully completing Phase 1 trials in the U.S. and South Africa, the company is preparing its Investigational New Drug (IND) applications for global Phase 2 studies.
공시 • Mar 12Dx & Vx Co., Ltd., Annual General Meeting, Mar 28, 2025Dx & Vx Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea
분석 기사 • Feb 14Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 32% LowerThe Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...
New Risk • Feb 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩65.0b market cap, or US$45.1m).
분석 기사 • Feb 12Is Dx & Vx (KOSDAQ:180400) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Dec 05Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 28%The Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...
New Risk • Nov 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩93.1b market cap, or US$66.7m).
분석 기사 • Oct 21Positive Sentiment Still Eludes Dx & Vx Co., Ltd. (KOSDAQ:180400) Following 27% Share Price SlumpDx & Vx Co., Ltd. ( KOSDAQ:180400 ) shareholders that were waiting for something to happen have been dealt a blow with...
공시 • Oct 04Dx & Vx Co., Ltd. (KOSDAQ:A180400) agreed to acquire remaining 37% stake in Avixgen, Inc. for KRW 4.7 billion.Dx & Vx Co., Ltd. (KOSDAQ:A180400) agreed to acquire remaining 37% stake in Avixgen, Inc. for KRW 4.7 billion on October 2, 2024. The consideration consists of 1.7 million common equity of Dx & Vx Co., Ltd. at a ratio of 0.290319 per common equity of Avixgen, Inc. The merger agreement is expected to signed on October 4, 2024. The expected completion of the transaction is December 17, 2024.
New Risk • Oct 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩131.4b market cap, or US$98.6m).
공시 • Sep 13Dx & Vx Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 42.37 billion.Dx & Vx Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 42.37 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 18,385,983 Price\Range: KRW 2230 Discount Per Security: KRW 44.6 Security Name: Common Stock Security Type: Common Stock Securities Offered: 614,017 Price\Range: KRW 2230 Discount Per Security: KRW 44.6 Transaction Features: Rights Offering
New Risk • Aug 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩111.4b market cap, or US$83.4m).
공시 • Jul 19DX&VX Is on Track and Accelerating the Development of Oral Obesity TreatmentDX&VX, which is gaining attention for developing an oral GLP-1 obesity treatment. The company is accelerating the optimization of new drug candidates. GLP-1 (glucagon-like peptide-1), an oral obesity treatment drug being developed by DX&VX, is a hormone that induces weight loss by suppressing appetite and increasing satiety to treat obesity. DX&VX researchers have developed organic compounds that can be taken orally once a day instead of through injections. While obesity treatment drug developers are conducting clinical trials for new oral GLP-1 organic compound drugs, the importance of this field is expanding day by day. To date, DX&VX has secured excellent candidate substances based on its AI-based innovative new drug design technology, and plans to submit patents for at least two more substances within this year. This research outcome is receiving significant attention from the industry and many pharmaceutical companies, both domestically and internationally, with some companies exploring the possibility of cooperation with DX&VX. Based on these achievements, DX&VX is expected to further accelerate the development of oral GLP-1 obesity treatments by utilizing various options such as early licensing out, global joint clinical trials, and research funding investment. As additional research results and patent applications continue, the obesity treatment drug being developed byDX&VX is expected to have stronger market competitiveness in the future.
분석 기사 • Jul 15Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 39% LowerUnfortunately for some shareholders, the Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has dived 39% in the last...
분석 기사 • May 31Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 37%The Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...
New Risk • May 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Market cap is less than US$100m (₩84.6b market cap, or US$61.5m).
New Risk • May 29New major risk - Revenue and earnings growthEarnings have declined by 9.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Market cap is less than US$100m (₩123.9b market cap, or US$90.8m).
Reported Earnings • Mar 23Full year 2023 earnings released: ₩929 loss per share (vs ₩47.45 loss in FY 2022)Full year 2023 results: ₩929 loss per share (further deteriorated from ₩47.45 loss in FY 2022). Revenue: ₩46.7b (up 45% from FY 2022). Net loss: ₩27.5b (loss widened ₩26.1b from FY 2022).
분석 기사 • Mar 18Investors Give Dx & Vx Co., Ltd. (KOSDAQ:180400) Shares A 25% HidingTo the annoyance of some shareholders, Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) shares are down a considerable 25% in the...
분석 기사 • Mar 08Dx & Vx (KOSDAQ:180400) Is Carrying A Fair Bit Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Oct 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).
New Risk • Jun 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).
공시 • Jun 15Dx & Vx Co., Ltd. announced that it has received KRW 9.223311402 billion in funding from Renaissance Asset Management and other investorsOn June 14, 2023, Dx & Vx Co., Ltd. closed the transaction.
공시 • May 25Dx & Vx Co., Ltd. (KOSDAQ:A180400) acquired Avixgen, IncDx & Vx Co., Ltd. (KOSDAQ:A180400) acquired Avixgen, Inc. recently.
공시 • May 17+ 1 more updateDxVx Appoints Kevin Kwon as New PresidentDxVx announced on May 16, 2023, the board of directors appointed Kevin Kwon, the former head of global business division at Hanmi Pharm.Co.,Ltd., as the new president. The new president, Kevin Kwon, holds a bachelor's and master's degree in applied bio-chemistry from Seoul National University, as well as a doctorate in management of technology from Korea University. He worked at the LG Chemical Biotech Research Institute and Regulatory Affairs (RA) Team in the LG Life Science. At Hanmi Pharm.Co.,Ltd, he served as the head of the global business division. He was a key person in global pharmaceutical business operations including global RA, overseas business development, overseas sales, clinical trials for new drug and licensing activities. In his career, he served as a joint professor at the Korea University Engineering Graduate School, an advisor for Korea Innovative Medicine Consortium (KimCo), an advisor for the formulation of bio similar regulations for the Ministry of Food and Drug Safety, a delegate for opening global markets at the Korea Health Industry Development Institute, and a professor for academic and business cooperation at Catholic University. Currently, he serves as a member of the special committee for global expansion at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. New president Kevin Kwon will be appointed as a board director from a shareholders' meeting. The former CEO, Sang Tae Park, has been nominated for the board director at Avixgen. In his new role, he intends to continue to make contributions to the company's growth by taking the lead in advancing the pipeline for new drugs and establishing a presence in the North American market.
Board Change • Apr 04Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.